Ellen G Chadwick

Summary

Affiliation: Northwestern University
Country: USA

Publications

  1. ncbi Long-term outcomes for HIV-infected infants less than 6 months of age at initiation of lopinavir/ritonavir combination antiretroviral therapy
    Ellen G Chadwick
    Division of Infectious Diseases, Children s Memorial Hospital, Northwestern University s Feinberg School of Medicine, Chicago, Illinois, USA
    AIDS 25:643-9. 2011
  2. ncbi Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results
    Ellen G Chadwick
    Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA
    AIDS 22:249-55. 2008
  3. ncbi Single-dose safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, in HIV-infected children
    Ram Yogev
    Division of Infectious Diseases, Children s Memorial Hospital, 2300 Children s Plaza, Box 155, Chicago, IL 60614, USA
    Antimicrob Agents Chemother 49:336-41. 2005

Detail Information

Publications3

  1. ncbi Long-term outcomes for HIV-infected infants less than 6 months of age at initiation of lopinavir/ritonavir combination antiretroviral therapy
    Ellen G Chadwick
    Division of Infectious Diseases, Children s Memorial Hospital, Northwestern University s Feinberg School of Medicine, Chicago, Illinois, USA
    AIDS 25:643-9. 2011
    ..To investigate the longitudinal pharmacokinetics, safety and efficacy of lopinavir/ritonavir (LPV/r) in HIV-infected infants initiating combination antiretroviral therapy (cART) between 2 weeks and 6 months of age...
  2. ncbi Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results
    Ellen G Chadwick
    Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA
    AIDS 22:249-55. 2008
    ..To investigate pharmacokinetics, safety and efficacy of lopinavir/ritonavir (LPV/r)-based therapy in HIV-1-infected infants 6 weeks to 6 months of age...
  3. ncbi Single-dose safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, in HIV-infected children
    Ram Yogev
    Division of Infectious Diseases, Children s Memorial Hospital, 2300 Children s Plaza, Box 155, Chicago, IL 60614, USA
    Antimicrob Agents Chemother 49:336-41. 2005
    ..Considerable interpatient variability was seen for all pharmacokinetic parameters of amprenavir. The results of this study suggest that 20 mg of amprenavir/kg administered twice a day should be used in future pediatric studies...